500mg Fulvestrant in HR+ MBC
To study the real world use of 500mg Fulvestrant in HR+ MBC.
Breast Cancer
PFS, Progression free survival, 6 weeks
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, 6 weeks
An observational, retrospective study of 500mg Fulvestrant in hormone receptor+/HER2- advanced breast cancer